Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdomyosarcoma 1Neoplasms 1Myelodysplastic Syndromes 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Fanconi Anemia 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 69fludarabine phosphate 66Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 48Whole-Body Irradiation 47Tacrolimus 44Busulfan 43Cyclosporine 38Azacitidine 35Methotrexate 28Filgrastim 27Antilymphocyte Serum 27Cytarabine 26Decitabine 23Melphalan 22Radiotherapy 21fludarabine 20venetoclax 16Methylprednisolone 16Cyclosporins 13Cord Blood Stem Cell Transplantation 13Injections 12Granulocyte Colony-Stimulating Factor 12Flow Cytometry 12Specimen Handling 11Etoposide 11Biopsy 11Stem Cell Transplantation 10Sirolimus 10Clofarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Chronic × prexasertib × Clear all
NCT02649764 2023-10-04

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡